A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110γ Isoform in Medulloblastoma Cell Proliferation and Chemoresistance

Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. We were interested in gaining further insight into the potential of targeting the human kinome as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small interfering RNA (siRNA) was used to downregulate the known human protein and lipid kinases in medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising ATR, LYK5, MPP2, PIK3CG, PIK4CA, and WNK4 were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed overexpression of LYK5 and PIK3CG. The results of the siRNA screen were validated by target inhibition with specific pharmacological inhibitors. A pharmacological inhibitor of p110γ (encoded by PIK3CG) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma. Mol Cancer Res; 9(7); 925–35. ©2011 AACR.

[1]  F. Speleman,et al.  The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors , 2010, Molecular Cancer Therapeutics.

[2]  H. Friess,et al.  Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer , 2010, Clinical Cancer Research.

[3]  K. Shin‐ya,et al.  Disabling c-Myc in Childhood Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor Cells by the Potent G-Quadruplex Interactive Agent S2T1-6OTD , 2010, Molecular Cancer Therapeutics.

[4]  Maria Deak,et al.  Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation , 2009, Science.

[5]  R. Bernards,et al.  Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer , 2009, Oncogene.

[6]  E. Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.

[7]  C. García-echeverría,et al.  PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. , 2009, Current opinion in cell biology.

[8]  D. Stearns,et al.  RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells , 2009, BMC Cancer.

[9]  O. Delattre,et al.  Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration , 2008, Clinical Cancer Research.

[10]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[11]  F. Khuri,et al.  LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. , 2008, Cancer research.

[12]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[13]  A. Thompson,et al.  Targeting AMPK: a new therapeutic opportunity in breast cancer. , 2008, Critical reviews in oncology/hematology.

[14]  P. Vogt,et al.  Oncogenic signaling of class I PI3K isoforms , 2008, Oncogene.

[15]  Jing Chen,et al.  Phosphoinositide 3‐kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death , 2008, International journal of cancer.

[16]  J. Grill,et al.  Recent development in chemotherapy of paediatric brain tumours , 2007, Current opinion in oncology.

[17]  O. Delattre,et al.  Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. , 2007, The Biochemical journal.

[18]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[19]  J. Brenton,et al.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.

[20]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[21]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[22]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[23]  D. Stearns,et al.  Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells , 2007, BMC Cancer.

[24]  C. Rommel,et al.  PI3Kγ inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature Reviews Drug Discovery.

[25]  Nir Hacohen,et al.  Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.

[26]  J. Gueulette,et al.  Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin. , 2006, Life sciences.

[27]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[28]  M. Lei,et al.  Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion , 2006, Molecular and Cellular Biology.

[29]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Jeffrey P. MacKeigan,et al.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.

[31]  Ran Guan,et al.  Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. , 2005, Cancer research.

[32]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[33]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[34]  R. Gilbertson,et al.  Medulloblastoma: signalling a change in treatment. , 2004, The Lancet. Oncology.

[35]  D. Rowitch,et al.  Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors , 2004, Development.

[36]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[37]  Roger E. Taylor,et al.  Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. , 2002, Medical and pediatric oncology.

[38]  S. Croul,et al.  Insulin-like growth factor I receptor activity in human medulloblastomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  R. Gilbertson.  Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. , 2002, European journal of cancer.

[40]  B. Decallonne,et al.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. , 2001, Methods.

[41]  M. Mareel,et al.  Tumour biology. Weakening link to colorectal cancer , 2001 .

[42]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[43]  S. Scherer,et al.  Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ , 2000, Nature.

[44]  S. Eksborg,et al.  Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. , 2010, Cancer research.

[45]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[46]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Matthias K Schwarz,et al.  PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature reviews. Drug discovery.

[48]  H. Lane,et al.  The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .

[49]  R. Gilbertson,et al.  ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. , 2003, Cancer research.

[50]  M. Scott,et al.  The developmental biology of brain tumors. , 2001, Annual review of neuroscience.

[51]  M. Mareel,et al.  Tumor biology: mouse models of colon cancer , 2001 .